FOR centuries, gout has been a deeply misunderstood disease, associated only with jolly, indulgent, and often big men. When Henry VIII was diagnosed, it became firmly entrenched in popular belief ...

The current strategy for managing chronic gout is the use of uric-acid-lowering drugs to reduce urate production or of a uricosuric agent to promote renal uric acid excretion. Probenecid is ...

Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy in achieving a target serum uric acid ...

The refractory gout market is growing because of the rising prevalence of gout brought on by aging populations and changes in ...

Uric acid crystals can accumulate under the skin and form lumps called "tophi." Chronic (long-term) gout can cause knee ...

A recent study published in Diabetes, Obesity and Metabolism has revealed the detrimental interplay between gout and chronic ...

Urate-lowering therapies benefited patients with gout and stage 3 chronic kidney disease without raising the risk of kidney ...

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...

The global intravenous pegloticase market is poised for substantial growth, projected to reach USD 11.61 Billion by 2033 from ...